Anti-Inflammation Stack

Overview

The Anti-Inflammation Stack groups three peptides that are each independently characterized in the preclinical literature as modulators of inflammatory signalling and tissue repair. It is supplied as six separate vials, so the material corresponds to three distinct bodies of published work rather than to a single studied formulation.

KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone. Brzoska and colleagues reviewed this peptide family as anti-inflammatory and protective agents in vitro and in vivo, and Dalmasso et al. reported that KPV is taken up through the PepT1 transporter and reduced intestinal inflammation in murine models.[14][15] Kelly et al. reported that immobilized GKPV inhibited TNF-α-stimulated NF-κB activity.[17]

TB-500 is the N-acetylated 17–23 fragment of Thymosin β4, an identity confirmed analytically by Esposito et al.[7] The LKKTETQ actin-binding motif it carries has been described by Sosne et al. as an active site of the parent protein, and Philp et al. reported that a synthetic peptide containing this domain promoted dermal wound repair in rodent models.[12][13]

BPC-157 is a synthetic pentadecapeptide derived from a sequence identified in gastric juice by Sikiric and colleagues, whose group developed the cytoprotection framework that organizes most of its literature.[1][2] Hsieh et al. associated its pro-angiogenic activity with VEGFR2 activation.[3]

No peer-reviewed study has evaluated these three peptides together as a stack. Every citation on this page describes an individual component tested on its own. Investigators should treat the kit as three separate research materials and refer to the dedicated KPV, TB-500, and BPC-157 entries for complete mechanism, applications, and reference lists.

Reported Mechanisms — Component by Component

Each section below summarizes the published mechanism of a single component. No combined mechanism is described in the literature, and none is asserted here.

1. KPV (20 mg across 2 vials) — Melanocortin-Derived Anti-Inflammatory Signalling

KPV corresponds to residues 11–13 of α-MSH. Hiltz and Lipton reported anti-inflammatory activity for this COOH-terminal fragment, and Getting et al. dissected the contributions of the core and C-terminal sequences.[16][20] Reported cellular routes include PepT1-mediated uptake in intestinal epithelium and inhibition of TNF-α-stimulated NF-κB activity.[15][17] Kannengiesser et al. reported anti-inflammatory potential in murine models of inflammatory bowel disease, and Xiao et al. examined nanoparticle-delivered KPV in a colitis model.[18][19]

2. TB-500 (40 mg across 2 vials) — G-Actin Binding and Cytoskeletal Dynamics

The LKKTETQ motif binds monomeric G-actin, the property that defines Thymosin β4 as an actin-sequestering protein.[8][13] For the full-length parent protein, Bock-Marquette et al. reported activation of integrin-linked kinase and promotion of cardiac cell migration, and Smart et al. reported epicardial progenitor mobilization and neovascularization.[10][11] Xing et al. reviewed the function and application of Thymosin β4 more broadly.[9] Note that TB-500 is a fragment and does not reproduce every reported activity of the full-length protein.[7]

3. BPC-157 (40 mg across 2 vials) — VEGFR2-Associated Angiogenic Signalling

Hsieh et al. reported that the pro-angiogenic activity of BPC-157 is associated with VEGFR2 activation and up-regulation in endothelial models.[3] Chang et al. reported effects on tendon outgrowth, cell survival, and cell migration in tendon fibroblast models.[4] Seiwerth et al. reviewed the wound-healing literature, and Xu et al. published a preclinical safety evaluation.[5][6]

No published pharmacokinetic, pharmacodynamic, or interaction study has evaluated KPV, TB-500, and BPC-157 administered together. Any combined behaviour is unstudied.

Research Applications (Component-Level)

The published work behind each vial in this kit falls into the following areas. Every study listed used a single peptide, not the stack.

1. Intestinal and mucosal inflammation models — KPV has been examined in murine colitis and inflammatory bowel disease models, including PepT1-mediated uptake and nanoparticle delivery formats.[15][18][19]
2. Dermal wound-repair models — a synthetic peptide containing the Thymosin β4 actin-binding domain promoted dermal wound repair in db/db diabetic and aged mice.[12]
3. Angiogenesis and endothelial models — BPC-157 has been associated with VEGFR2 activation; full-length Thymosin β4 has been reported to mobilize epicardial progenitors.[3][11]
4. Tendon and connective-tissue models — BPC-157 has been studied in tendon fibroblast outgrowth and migration paradigms.[4]
5. NF-κB and cytokine signalling assays — KPV has been reported to inhibit TNF-α-stimulated NF-κB activity in cell models.[17]
6. Analytical and doping-control chemistry — the identity of the TB-500 fragment has been characterized analytically, which matters for assay design.[7]

Important: no cited study used the combined stack. Researchers should not assume that single-agent findings carry over to co-administration.

Preclinical Research Summary (Component-Level)

No peer-reviewed study has evaluated this six-vial stack as a unit. The table below lists representative findings for each component individually. Full per-component data and complete reference lists are on the dedicated KPV, TB-500, and BPC-157 pages.